ANIK vs. ANGO, OFIX, SIBN, ARAY, SRDX, ATRI, OSUR, CERS, UTMD, and WST
Should you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include AngioDynamics (ANGO), Orthofix Medical (OFIX), SI-BONE (SIBN), Accuray (ARAY), Surmodics (SRDX), Atrion (ATRI), OraSure Technologies (OSUR), Cerus (CERS), Utah Medical Products (UTMD), and West Pharmaceutical Services (WST). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
In the previous week, AngioDynamics had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 10 mentions for AngioDynamics and 7 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.40 beat AngioDynamics' score of 0.14 indicating that Anika Therapeutics is being referred to more favorably in the media.
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 5.9% of Anika Therapeutics shares are owned by company insiders. Comparatively, 5.1% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
AngioDynamics has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Anika Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
AngioDynamics received 62 more outperform votes than Anika Therapeutics when rated by MarketBeat users. However, 64.24% of users gave Anika Therapeutics an outperform vote while only 60.74% of users gave AngioDynamics an outperform vote.
Anika Therapeutics presently has a consensus price target of $30.50, suggesting a potential upside of 18.91%. AngioDynamics has a consensus price target of $13.25, suggesting a potential upside of 109.98%. Given AngioDynamics' stronger consensus rating and higher probable upside, analysts clearly believe AngioDynamics is more favorable than Anika Therapeutics.
Anika Therapeutics has a net margin of -45.39% compared to AngioDynamics' net margin of -60.21%. Anika Therapeutics' return on equity of 0.48% beat AngioDynamics' return on equity.
Summary
Anika Therapeutics and AngioDynamics tied by winning 9 of the 18 factors compared between the two stocks.
Get Anika Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anika Therapeutics Competitors List
Related Companies and Tools
